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Reconstructive transplantation has emerged as clinical reality over the past decade. Long-
term graft acceptance has been feasible in extremity and facial vascularized composite
allotransplantation (VCA) under standard immunosuppression. Minimizing overall burden
of lifelong immunosuppression is key to wider application of these non-life saving grafts.
Allograft tolerance is the holy grail of many cell-based immunomodulatory strategies.
Recent protocols using mesenchymal stem cells from bone marrow and adipose tissue
offer promise and potential in VCA. This article provides an overview of the experimental
basis, the scientific background and clinical applications of stem cell-based therapies in the
field of reconstructive allotransplantation.
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INTRODUCTION
Complex reconstructions after major trauma are limited by avail-
able tissues, morbidity from extensive surgery, prolonged rehabil-
itation, suboptimal results, and costs of multiple surgeries. For
such intricate injuries, vascularized composite allotransplanta-
tion (VCA) can achieve optimal restoration of tissue deficits with
improved functional and esthetic results, enabling social and pro-
fessional reintegration. During the past decade, more than 100
reconstructive transplant procedures have been performed around
the world, including over 90 hand and 24 facial transplants with
encouraging overall outcomes (1–3).
Like solid organ transplants,VCA requires long-term multidrug
immunosuppression to prevent graft rejection mediated predom-
inantly by the highly immunogenic skin component in these allo-
grafts. Medication toxicity could result in metabolic, infectious, or
neoplastic complications. VCA is inherently different from solid
organ transplantation in its non-life saving, yet life-enhancing
impact on recipients. Further,unlike solid organs,clinical success is
dictated not only by graft acceptance and survival, but also by nerve
regeneration, which determines ultimate functional outcomes.
These characteristics of VCA, drive the debate focused on the
risks of lifelong immunosuppression mandated for graft survival
balanced against the benefits of functional and quality of life out-
comes. Thus, implementation of cellular therapies that integrate
the concepts of immune regulation for graft acceptance with those
of nerve regeneration could optimize the outcomes of these recon-
structive modalities and minimize overall burden of immuno-
suppression. Such strategies could expand clinical feasibility and
realize routine applicability of reconstructive transplantation.
Mesenchymal stem cells (MSCs) are pluripotent cells that are
present in multiple tissues, including bone marrow (BM), adipose
tissue, skin, muscle, blood, and placenta and can be isolated and
expanded ex vivo. MSCs are capable of differentiation in vitro along
multiple mesenchymal lineages such as osteocytes, chondrocytes,
myocytes, adipocytes, and Schwann cells (SC) thereby emerging
as a promising tool for tissue engineering and cell therapy.
Current literature on MSCs points to a wide range of immuno-
logical functions and interactions with other cell types (4, 5).
Recent data support findings that MSCs mediate their actions
through multiple mechanisms including paracrine effects. Various
groups have shown some key differences between adipose-derived
MSCs (AD-MSCs) and bone marrow derived MSCs (BM-MSCs)
in vitro and in vivo (6–8). In particular, it has been demonstrated
that MSCs have the capacity to suppress T cell activation and pro-
liferation (9). Compared to BM, adipose tissue is a rich source of
MSCs with up to 10-fold higher yield of MSCs (10). More recent
publications demonstrate that AD-MSCs might also have higher
immunomodulatory and immunosuppressive potential in vitro as
compared to BM-MSCs (11–20). The ease of procurement of large
volumes of AD-MSCs through techniques such as liposuction is an
important benefit because of expeditious approach and minimal
morbidity. Depending on time considerations for cell expansion,
the overall duration of cell retrieval to cell infusion could be signif-
icantly shortened for AD-MSCs as compared to MSCs from other
sources.
There is a growing complement of first in human studies
addressing potential of MSC based cell therapies in autoimmune
diseases, facilitation of hematopoietic stem cell engraftment in
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BM transplantation and in solid organ transplantation (4, 21, 22).
Recent experimental and clinical studies highlight their potential
for immunomodulation, tolerance induction, and prophylaxis and
treatment of graft versus host disease (GvHD) (23–25). In VCA,
the efficacy and effectiveness as well as mechanisms and outcomes
of such therapies may be affected by the antigenicity of the skin
component (26), as or by the differential tissue composition of
these grafts.
IMMUNOLOGICAL FUNCTION OF MSCs
The effects of MSCs on innate and adaptive immunity have been
reported in the literature (4, 5). MSCs modulate the innate func-
tion of monocytes, macrophages, natural killer (NK) cells, and
dendritic cells (DCs). They are capable of modifying the matura-
tion of DC, thereby inhibiting their antigen-presenting function
and inducing the generation of tolerogenic DCs. This results
in downregulated MHC II and chemokine expression (27–30).
MSCs show intermediate expression of MHC I and do not express
MHC II on their surface, which reduces their antigenicity. How-
ever the intracellular MHC II can become relevant when NK lyse
transplanted MSCs (31, 32). In addition, MSCs also affect innate
immunity through HLA-G expression leading to inhibition of NK
cells and reduction of IFN-g expression (33, 34). English et al. (35)
have shown that MSCs can directly induce regulatory T cell (Treg)
generation. Mediators of Treg generation include indoleamine
2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and IFN-g (4).
However, MSCs inhibit the activation of cytotoxic lymphocytes
and immunoglobulin production through activated and prolifer-
ating B cells (36). The nitric oxide (NO) system as well as factors
involved in stem cell recruitment like SDF-1, growth factors like
VEGF and cytokines like IL-6, IL-8, and IL-10 have been shown
to be important players in MSC dependent effects on adaptive
immune responses (4, 5) (Figure 1).
MSCs PROMOTE NERVE REGENERATION
The functional advantages of VCA over prosthetic fitting rely
not only on motor recovery but also sensory recovery follow-
ing regeneration of peripheral nerves and reintegration of neu-
ronal pathways into the premotor cortex of the brain. MSCs have
shown promise in improving clinical and electrophysiological out-
comes in animal models of peripheral nerve injury (37–39). In
comparison to local delivery, some groups have demonstrated
significantly accelerated functional neuronal recovery following
systemic administration of MSCs (40). The postulated mecha-
nisms for such outcomes could include direct and paracrine effects
(38, 41).
MSC USE IN ALLOTRANSPLANTATION
Bartholomew et al. (9) first described prolongation of skin graft
survival after allotransplantation in primates with a single applica-
tion of expanded BM-MSCs at day 0. Sbano et al. (42) also reported
similar results with cultured BM-MSC administered on day 0 and
3 in a rat model. Skin graft survival was prolonged, although grafts
were rejected without supplementary immunosuppression.
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FIGURE 1 | Immunological Function of MSCs on different cell types of
the innate and adaptive immunosystem. MSC, mesenchymal stromal
cell, characterized by surface antigens CD29, CD73, CD90 (CD105), MHC
I; cell types: B cells, T Cells, Treg; regulatory T cells; DC, dendritic cells
(tolerogenic, i/m, immature/mature), monocytes, macrophages, NK,
natural killer cells. Arrows indicate activation or induction, T-bars indicate
blockade of function or activation, in particular inhibition of proliferation,
differentiation, cytotoxicity, maturation. The NO system is closely involved
in creating an immunosuppressive microenvironment. Via an indirect way
the generation of tolerogenic DCs induces Tregs. MSCs can also directly
activate Treg generation. These Tregs play a significant role in the
development of tolerance.
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Solari et al. (43) demonstrated long-term islet allograft survival
in rats using syngeneic MSCs. In this study, repetitive applica-
tion of syngeneic BM-MSCs was superior to allogeneic BM-MSCs.
However, long-term tolerance could only be achieved in 40%, and
cells were expanded up to P8. Their inherent immunomodula-
tory function has promoted use of MSCs in BM transplantation,
solid organ transplantation, and treatment of GvHD (30). BM-
MSCs have been used in experimental animal heart, liver, kidney,
and islet transplantation (14, 30, 43–49). Immunomodulation was
related to the suppression of alloreactive effector lymphocytes (50)
through expression of a variety of cytokines (51–53) (Figure 1)
and generation of CD4/CD25/FoxP3 Tregs that achieved long-
term tolerance in animal studies via adaptive immune mechanisms
(31, 50). Data on AD-MSCs in solid organ transplantation is
scarce; however sources for MSCs other than BM have been sup-
ported/investigated (54). In addition, studies have confirmed the
multifaceted properties of MSCs including their potential as part
of induction therapy (55), in GvHD (56), tolerance induction (55,
57), and facilitating engraftment of BM transplants (58, 59). Sev-
eral clinical trials have demonstrated their immunosuppressive
function that could have potential in autoimmune disease (32, 60,
61). Such properties could offer potential for MSCs in acute and
chronic rejection after VCA. MSCs have been successfully used
in pediatric patients as rescue therapy of GVHD and repetitive
rejection of BM transplants (62).
CRITICAL ISSUES FOR MSC USE IN VCA
The success of organ transplantation and VCA is dependent on
graft acceptance in the absence of GvHD. Various induction and
maintenance regimens have been successful in controlling acute
rejection. All these drugs have their role in VCA for specific
immunosuppressive functions, but their unwarranted collateral
effects on MSCs are less well investigated.
Several studies in solid organs have reported pre-transplant,
peri-transplant, or post-transplant use of MSCs for immunomod-
ulation (63–65). However, the negative effects of the depletion
regimens that include irradiation, and polyclonal (antithymocyte
globulin/serum), or monoclonal antibodies (e.g., alemtuzumab)
on MSC recruitment, homing, and function remain to be clarified.
INTERACTION WITH IMMUNOSUPPRESSIVE DRUGS
Several immunosuppressive drugs significantly affect in vitro
activity of MSCs. Hoogduijn et al. (66) investigated the in vitro
effect of tacrolimus, rapamycin, and MPA on human MSCs and
vice versa. Exposure of MSCs to high dosages of tacrolimus was
toxic and reduced cell viability. While tacrolimus did not inhibit
proliferation rates of MSCs, rapamycin, and MPA led to a dose-
dependent reduction of proliferation and differentiation at thera-
peutic dosage levels. Unlike rapamycin, tacrolimus did not affect
the osteogenic differentiation potential of MSCs (67). The effects
of Cyclosporin A (CsA) on MSCs were insignificant. Some authors
demonstrated a synergistic immunosuppressive effect of MSCs
and MPA (68, 69). However, the immunomodulatory properties
of MSCs were antagonized by rapamycin and tacrolimus. In vivo
experiments support these findings of synergistic or opposing
effects between MSC and pharmacological immunosuppression
(68, 70). Hoogduijn’s et al (66) reported that MSCs inhibited
the suppressive effect of tacrolimus and rapamycin on alloreactive
lymphocytes but had no effect on MPA.
TIMING AND DOSAGE OF MSCs
Currently, there is no consensus on dosing and timing of admin-
istration of MSCs in cell-based VCA protocols. Experimental
studies indicate that the dosage of MSCs showing beneficial results
ranges from 5× 105 to 5× 107 cells/kg body weight and time point
(Table 1). In rats, the total amount of BM-MSCs administered
over time was 6−10× 106 cells, whereas in pigs total amounts
from 5 to 12.5× 107. BM-MSCs were used. In a study utilizing
AD-MSCs, as many as 24× 106 cells/kg bodyweight were adminis-
tered over three time points (58, 59, 71). MSCs were administered
as early as day −30 to as late as +21 relative to transplantation
or at different frequency in the interim (57–59). The time point
was chosen with regards to the desired effect such as induction,
immunomodulation, or support of BM engraftment.
HOMING OF MSCs/CHIMERISM
Eggenhofer et al. (72) recently reported a murine study reduced life
span of intravenously delivered cultured MSCs due to entrapment
in the lung capillaries or liver sinusoids. Others have shown distri-
bution to other organs like kidney and spleen, BM, and peripheral
blood (73). Kuo et al. (58) demonstrated recruitment and homing
of MSCs to perivascular sites with long-term survival in VCA mod-
els. In addition peripheral blood chimerism after VCA with MSC-
co-transplantation was demonstrated in pig and rat models (57–
59). Indeed, the first-pass clearance of MSCs in lung and liver may
be an obstacle for these cell therapies (74, 75). Several strategies
including vasodilation, co-transplantation, and repetitive infu-
sions have been suggested to increase cell passage. Freshly isolated
MSCs have been shown to be superior to culture-expanded MSCs
in terms of lower entrapment potential due to smaller size as well
as better homing potential (76). They are found in high number
in sites of trauma and ischemia after several days (77).
CULTURED MSCs
For therapeutic indications, MSCs need to be expanded in culture
to achieve sufficient numbers for transplantation. Karp and Leng
(78) reported that the culture medium and conditions are likely
to influence the properties of MSCs as well as their morphol-
ogy (79, 80). The number of passages inversely correlates with
the number of surface antigens and homing potential (81–84).
Cultured MSCs may be morphologically indistinguishable from
fibroblasts and even show similar cell-surface markers, differen-
tiation potential, and immunologic properties (80). Multiple cell
passages not only affect proliferation and differentiation but also
alter cell-surface antigens and cytokine production (85, 86). To our
knowledge, there is no study to date on the immunomodulatory
potential of long-term-cultured MSCs. In our view, short-term
culture of MSCs (<P3) and freshly isolated MSCs must be given
preference in cell therapy protocols until we gain more insights
into the properties of expanded MSCs.
MSCs IN VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION
Only a few groups have advocated the use of BM-MSCs or
AD-MSCs for immunomodulatory strategies in VCA (Table 1).
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Table 1 | Overview of the currently available experimental literature on MSC based cellular therapy for immunomodulation inVCA.
Reference Type of
graft
Species MSCs
amount/type
MSC
application
Induction
regimen
Immuno-
suppression
Main outcome
Pan et al. (59) Hindlimb Rat 107 BM-MSCs
(allogeneic)
Day −30 Irradiation,
ALS, BMT
Rapamycin Chimerism in peripheral blood
Tolerance (>100 days)
Protection against GvHD
Kuo et al. (58) Hindlimb Pig 107 BM-MSCs
(allogeneic)
Day −1, +3,
+7, +14, +21
Irradiation,
BMT
Cyclosporin Perivascular MSC engraftment (graft)
Chimerism in peripheral blood
Tolerance (>200 days)
Protection against GvHD
Treg ⇑
Kuo et al. (87) Hindlimb Pig 107 BM-MSCs
(allogeneic)
Day −1, +3,
+7, +14, +21
Irradiation Cyclosporin Tolerance (>120 days)
Treg ⇑
Kuo et al. (57) Hindlimb Rat 2×106 AD-MSCs
(allogeneic)
Day +7, +14,
+21
ALS Cyclosporin Tolerance (>150 days)
Chimerism peripheral blood
Treg ⇑
IL-10 ⇑
Kuo et al. (88) Face Pig 2.5×107 BM-MSCs
(allogeneic)
Day −1, +3,
+7, +14, +21
N/A Cyclosporin Treg ⇑
IL-10 ⇑
Aksu et al. (71) Skin flap Rat 2–3×106 (repetitive)
BM-MSCs
(syngeneic)
Days 0, +7,
+14, and +21
Irradiation
BMT
(repetitive)
Cyclosporin Syngeneic MSCs limit toxicity of
allogeneic BMT
Prolongation of tolerance
Enhanced mixed chimerism
Despite growing enthusiasm, the basic experience is limited to few
experimental studies with MSCs. Aksu et al. (71) reported that
co-administration of host BM-MSCs with unmodified donor BM
and immunosuppression (CsA+ irradiation) enabled prolonged
survival of full MHC mismatched rodent vascularized skin grafts
with generation of mixed chimerism and absence of GvHD. Out-
comes positively correlated with number of times the BM-MSCs
were administered. Pan et al. (59) reported a rat hindlimb VCA
model where limb transplants were performed a month after
conditioning with total body irradiation, and anti-lymphocyte-
serum followed by allogeneic BM-MSC and BM infusion. This
resulted in stable chimerism, donor specific tolerance, and no
GvHD. Allogeneic BM-MSC transplantation with or without co-
transplantation of BM has been shown to be successful in prolon-
gation (>200 days) of pig limb allograft survival after irradiation
and CsA treatment (58, 87). Repetitive high dose BM-MSC treat-
ment was also successful in prolonging survival in a pig hemi-facial
transplantation model without conditioning therapy (88). The
authors reported only mild rejection of the graft (Grade I–II),
improved under CsA treatment. The positive effects of BM-MSCs
on rejection grades were correlated to IL-10 upregulation and Treg
induction. Despite the prolongation, all grafts succumbed within
90 days. In a different approach, Kuo et al. (57) administered three
fold numbers of AD-MSCs under temporary immunosuppres-
sion in a rat hindlimb allotransplantation model. After cessation
of immunosuppression, this regimen prolonged allograft survival
significantly with stable tolerance in 89% for>150 days. Treg pop-
ulations were significantly increased and elevated donor lymphoid
cell counts (RT1n) resulted in stable peripheral blood chimerism
until endpoint. The same group conducted a study in a swine
hindlimb allotransplantation model using BM-MSCs, irradiation,
and short-term CsA. They were able to demonstrate prolongation
of the survival (>100 days in 67%) and an increase of the Treg
population.
CONCLUSION
Taken together, emerging literature evidence highlights the poten-
tial promise of MSC based cellular therapies for immunomod-
ulation and neurodegeneration in VCA. Extensive experimental
and clinical studies in the areas of solid organ transplantation,
hematopoietic stem cell co-transplantation and autoimmune dis-
ease underscore the relevance and impact of MSC based therapies
in VCA. Traditionally, the chief obstacle hampering application
of BM-MSCs has been the limited cell yield and requirement for
donor cell expansion. The high cell yields of AD-MSCs from adi-
pose sources obtained through easy, fairly non-invasive techniques
have enabled expeditious cell processing, thus expanding the clini-
cal feasibility of these therapies. These advantages, combined with
the insights supporting the superior immunomodulatory poten-
tial of AD-MSCs versus BM-MSCs truly advocate adipose-based
cellular therapies. The higher cell yields also facilitate repetitive
infusion both systemically and locally in the graft. Freshly iso-
lated AD-MSCs can overcome the loss of viability and entrapment
during the first-pass phenomenon in the capillary systems of the
lung. Importantly, MSCs mediate paracrine effects on remote tis-
sues through specific cytokines, chemokines, and growth factors.
It still remains to be defined if such paracrine effects mediate
also tolerogenic or immunomodulatory effects in VCA or other
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applications. Future protocols should carefully address the dosing
and timing of MSC administration and the effects of conditioning
regimens and maintenance immunosuppression on function of
these cells. Most notably, the effect of MSC based strategies on
nerve regeneration, critical for functional outcomes in VCA offers
an uncharted area of investigation. Thus far, only one donor
BM cell-based protocol has been clinically evaluated in human
upper extremity VCA (Pittsburgh Protocol) and involves mega-
dose donor derived BM infusion after at day 11–14 after surgery
(89). Insights into the impact of such protocols in minimizing the
need for dosing, frequency, and duration of immunosuppression
are just emerging. Meanwhile, we must continue to explore the
multifaceted potential of MSCs in experimental VCA to further
fine tune standard protocols as used in conventional VCA or solid
organ transplantation. The true clinical scope and impact of dis-
parate VCA strategies will only be realized when such protocols
enable optimization of the functional and immunological benefits
of these novel reconstructive procedures while reducing long-term
risk of lifelong immunosuppression.
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